Status:
COMPLETED
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
Lead Sponsor:
University of Nebraska
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Kidney Cancer
Melanoma (Skin)
Eligibility:
All Genders
19-120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help...
Detailed Description
OBJECTIVES: * Determine the relationship of peripheral blood lymphocyte phenotype pattern in patients with metastatic renal cell carcinoma or metastatic melanoma to response to high-dose aldesleukin ...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic renal cell carcinoma or metastatic melanoma
- Must be receiving treatment with high-dose aldesleukin as part of standard therapy
Exclusion
- none
Key Trial Info
Start Date :
October 2 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 16 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00617799
Start Date
October 2 2007
End Date
April 16 2010
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center, Eppley Cancer Center
Omaha, Nebraska, United States, 68198-6805